Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (2): 131-135.doi: 10.35541/cjd.20200483
• Original Articles • Previous Articles Next Articles
Zhang Yuexin, Chen Xixue
Received:
2020-05-20
Revised:
2020-10-19
Online:
2021-02-15
Published:
2021-01-29
Contact:
Chen Xixue
E-mail:xixue_chen@163.com
Zhang Yuexin, Chen Xixue. Two cases of bullous pemphigoid after long-term treatment with toripalimab[J]. Chinese Journal of Dermatology, 2021, 54(2): 131-135.doi:10.35541/cjd.20200483
[1] | Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper[J]. Ann Oncol, 2016,27(4):559⁃574. doi: 10.1093/annonc/mdv623. |
[2] | 李明, 周博洋, 李邻峰. PD⁃1/PD⁃L1抑制剂的皮肤不良反应[J]. 中国麻风皮肤病杂志, 2019,35(8):509⁃512. |
[3] | Carlos G, Anforth R, Chou S, et al. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab[J]. Melanoma Res, 2015,25(3):265⁃268. doi: 10.1097/CMR.0000000000000155. |
[4] | Lopez AT, Khanna T, Antonov N, et al. A review of bullous pemphigoid associated with PD⁃1 and PD⁃L1 inhibitors[J]. Int J Dermatol, 2018,57(6):664⁃669. doi: 10.1111/ijd.13984. |
[5] | Damsky W, Kole L, Tomayko MM. Development of bullous pemphigoid during nivolumab therapy[J]. JAAD Case Rep, 2016,2(6):442⁃444. doi: 10.1016/j.jdcr.2016.05.009. |
[6] | Papay J, Krenacs T, Moldvay J, et al. Immunophenotypic profiling of nonsmall cell lung cancer progression using the tissue microarray approach[J]. Appl Immunohistochem Mol Morphol, 2007,15(1):19⁃30. doi: 10.1097/01.pai.0000213143. 32030.f5. |
[7] | Krenacs T, Kiszner G, Stelkovics E, et al. Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis[J]. Histochem Cell Biol, 2012,138(4):653⁃667. doi: 10.1007/s00418⁃ 012⁃0981⁃9. |
[8] | Altman EM. Novel therapies for pemphigus vulgaris. Am J Clin Dermatol, 2020,21(6):765⁃782. doi: 10.1007/s40257⁃020⁃00 544⁃w. |
[9] | Stingeni L, Bianchi L, Minotti V, et al. Erlotinib⁃induced bullous pemphigoid[J]. J Am Acad Dermatol, 2012,67(5):e199⁃201. doi: 10.1016/j.jaad.2012.01.034. |
[10] | Jour G, Glitza IC, Ellis RM, et al. Autoimmune dermatologic toxicities from immune checkpoint blockade with anti⁃PD⁃1 antibody therapy: a report on bullous skin eruptions[J]. J Cutan Pathol, 2016,43(8):688⁃696. doi: 10.1111/cup.12717. |
[11] | Grän F, Goebeler M, Gesierich A. Bullous pemphigoid developing upon immune checkpoint inhibition with nivolumab[J]. Eur J Dermatol, 2019,29(4):448⁃449. doi: 10.1684/ejd.2019. 3614. |
[12] | Aggarwal P. Disproportionality analysis of bullous pemphigoid adverse events with PD⁃1 inhibitors in the FDA adverse event reporting system[J]. Expert Opin Drug Saf, 2019,18(7):623⁃633. doi: 10.1080/14740338.2019.1619693. |
[13] | Weber JS, Hodi FS, Wolchok JD, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma[J]. J Clin Oncol, 2017,35(7):785⁃792. doi: 10.1200/JCO.2015.66.1389. |
[14] | Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune⁃related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2018,36(17):1714⁃1768. doi: 10.1200/JCO.2017.77.6385. |
[15] | Siegel J, Totonchy M, Damsky W, et al. Bullous disorders associated with anti⁃PD⁃1 and anti⁃PD⁃L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy[J]. J Am Acad Dermatol, 2018,79(6):1081⁃1088. doi: 10.1016/j.jaad.2018. 07.008. |
[1] | Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 0(4): 20200767-e20200767. |
[2] | Gao Ni, Liu Yu, Wang Lei, Liu Ling, Gao Tianwen, Li Kai . Clinical and histopathological analysis of five cases of solitary dermal melanoma [J]. Chinese Journal of Dermatology, 2022, 0(2): 20200775-e20200775. |
[3] | Dong Dong, Liu Tianyi. Cell metabolism and metastasis of cutaneous malignant melanoma [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210023-e20210023. |
[4] | Chen Fangqi, Liang Yan, Wu Ting, Huang Changzheng. Associations between m6A RNA methylation and cutaneous melanoma [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210064-e20210064. |
[5] | Chen Yi, Song Xiuzu. Role of transient receptor potential channels in melanocytes and their related diseases [J]. Chinese Journal of Dermatology, 2022, 0(1): 20200958-e20200958. |
[6] | Yao Xiaodong, Cui Xiaomei, Liu Xiaoyu, Wu Xiaoyan, Shen Congcong, Chen Xiaodong. Role of long non-coding RNA 068 in the migration of melanoma cells [J]. Chinese Journal of Dermatology, 2022, 55(1): 31-39. |
[7] | Cao Meng, Hong Anlan, Wang Yan, Fang Fang. Clinical progress in pediatric melanoma [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210158-e20210158. |
[8] | Guo Wei, Zhao Tao, Guo Weinan, Ma Cuiling, Gao Tianwen, Zhao Jianhong, Li Bing. Surgical treatment strategies and outcomes of early-stage nail apparatus melanoma: a retrospective analysis of 115 cases [J]. Chinese Journal of Dermatology, 2021, 54(9): 777-784. |
[9] | Chen Fengming, Kang Hanmei, Gao Tianwen, Fu Meng, Wang Lei, Liu Ling. Clinicopathological features of 10 cases of congenital melanocytic nevi complicated by proliferative nodules [J]. Chinese Journal of Dermatology, 2021, 54(9): 785-789. |
[10] | Zhang Xiao, Fu Meng, Wang Lei, Liu Yu, Gao Tianwen, Liu Ling. Analysis of 118 cases of clinically misdiagnosed cutaneous melanoma [J]. Chinese Journal of Dermatology, 2021, 54(9): 771-776. |
[11] | Wu Yuhao, Zhang Guolong, Wang Xiuli. Tertiary lymphoid structures in malignant melanoma [J]. Chinese Journal of Dermatology, 2021, 54(9): 827-830. |
[12] | Wang Daguang, Jiang Jiayi. Considerations in the diagnosis and treatment of several nail diseases [J]. Chinese Journal of Dermatology, 2021, 54(8): 733-737. |
[13] | Yu Yingyuan, Li Ying, Yu Zengyang, Zheng Jianfeng, Zhang Xilin, Ding Yangfeng, Shi Yuling, . Efficacy and safety of infliximab in the treatment of severe plaque psoriasis and its effect on the expression of programmed cell death-1 and programmed cell death ligand-1 [J]. Chinese Journal of Dermatology, 2021, 54(7): 590-596. |
[14] | Wang Yanqing, Guo Ying. Pathological features and diagnosis of Spitz nevus [J]. Chinese Journal of Dermatology, 2021, 54(4): 308-312. |
[15] | Gao Meiyan, Zhao Jianhong, Zhao Tao, Li Bing, Tian Pei, Wang Guan, Ma Cuiling, Gao Tianwen, Guo Weinan. Clinicopathological characteristics and prognosis of 87 cases of trauma-related melanomas [J]. Chinese Journal of Dermatology, 2021, 54(4): 289-293. |
|